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 ABSTRACT                                                                                                                                            
Detection of human telomerase reverse transcriptase 
messenger RNA in urine of high risk patients as a non 
invasive molecular diagnostic tool for urinary bladder 
cancer in Egyptians
Susan F. Helal1, Heba SH. Kassem1,2, Wael M. Sameh3 and Samar N. El- 
Achy1
1Pathology department, 2Clinical Genomics Centre, 3Urology Department, 
Faculty of Medicine, University of Alexandria, Egypt
Introduction and Objectives: Bladder cancer is an important national health 
problem as it is the leading cancer in men in Egypt. Cystoscopy and biopsy, 
currently remains the gold standard procedure for diagnosis, yet, it is invasive 
and costly. Urinary cytopathology remains to be the only non-invasive alter-
native method for diagnosis. Although it is tumour specifi c, yet it has a poor 
sensitivity, especially for low grade tumours. Detection of Telomerase enzyme 
in exfoliated urinary cells is a potentially good molecular diagnostic marker in 
bladder cancer, since the catalytic subunit of this enzyme (hTERT) proved to 
be essential for cellular immortality and oncogenesis. 
Subjects and Methods: The study comprised 39 patients (36 with urothelial 
carcinomas and 3 cases were squamous cell carcinoma) with bladder cancer 
and 22 non cancer control (including 14 patients with benign urological dis-
orders and 8 healthy volunteers). The urine sample was split into two aliquots 
one was used to undertake RNA extraction and hTERT/GAPDH RT-PCR semi-
quantitative assay and the second for cytological examination. Cystoscopy was 
considered the reference standard for the identifi cation of bladder cancer. 
Results: The hTERT/GAPDH RT-PCR test showed signifi cantly higher diag-
nostic sensitivity than cytology (84% Vs. 75% p<0.008) for confi rmed UCC, 
particularly for low grade non-muscle invasive UCC (82% Vs. 64% p<0.005). 
On combining the two tests a sensitivity of 95% was obtained. A positive 
hTERT expression was detected 4-5 months earlier than cystoscopic evidence 
of recurrence in 2 patients during their follow up. 
Conclusion: In this pilot study, detection of hTERT expression in urine has 
shown to be a more sensitive marker for diagnosis of bladder cancer than cytol-
ogy. The combination of urinary hTERT mRNA with cytological testing aug-
ments the sensitivity for the non-invasive early diagnosis of bladder cancer. 
This fi nding warrants further extended study to validate the potential role of 
hTERT expression as a diagnostic non invasive tool for high risk patients and 
detection of recurrence in bladder cancer in Egypt.




Bladder cancer, telomerase, hTERT 
RT-PCR, urine cytology.
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INTRODUCTION                                  
Bladder cancer is an important national 
health problem. It is the leading cause 
of cancer in Egyptian males.1,2. Bladder 
cancer has a high recurrence rate (70%), 
with 20-30% progressing to invasive 
disease3,4. Hence, optimal management 
of this disease requires early detection 
of both primary tumour as well as re-
currences.
Cystoscopy and biopsy, currently re-
mains the gold standard procedure for 
diagnosis, yet, it is uncomfortably in-
vasive, costly and sophisticated5,6. Uri-
nary cytopathology has remained the 
only alternative non-invasive method 
for examining patients presenting with 
hematuria, for primary bladder cancer, 
or recurrence. Although cytology is tu-
mour specifi c, its value as a diagnostic 
test is quite limited due to its poor sensi-
tivity, especially for low grade tumours 
(22-62%) in which the morphological 
features of the neoplastic cells are in-
distinguishable from the normal urothe-
lial cells7-10. It is also highly dependent 
upon proper sampling and is open to 
subjective interpretation.11
Bladder cancer is one of the most ame-
nable carcinomas for tumour marker 
development as many of them are ei-
ther secreted in urine, or are tumour 
cell-associated, which can be detected 
by analyzing exfoliated cells in urine 
specimens. The impetus for develop-
ing new bladder tumour markers comes 
from the idea that an accurate biomark-
er can reduce the number of cystosco-
pies performed each year and thus, cut 
down the frequency of this invasive and 
costly procedure.
Many new urine-based tests for blad-
der cancer have been developed in-
cluding fl uorescent in situ hybrid-
ization (FISH)12, immunocytology 
(ImmunoCyt™)13, survivin14, cytok-
eratins (19, CYFRA 21-1)15, fl ow cy-
tometry and Quanticyt™15, bladder 
tumour-associated antigen (BTA) test16, 
nuclear matrix protein 22 (NMP22) 
test16. Among them, BTAstat, BTA-
trak, NMP22, ImmunoCyt and FISH 
(UroVysion) have been approved by the 
food and drug association (FDA)17,18.
Among the markers proposed to im-
prove diagnostic sensitivity in urine, in-
creasing attention has been focused on 
the role of Telomerase enzyme in exfo-
liated urinary cells as a potential can-
didate for bladder cancer detection19,20. 
Telomerase (an enzyme fi rst detected 
in human cancer cell lines in 1994)21 is 
a unique cellular reverse transcriptase 
(RT) that functions to elongate telo-
meric ends of chromosomes, thus com-
pensating for progressive erosion of 
telomeric sequences inherent to DNA 
replication.5,22
The Telomerase enzyme is composed of 
3 main parts: an enzymatic human Te-
lomerase reverse transcriptase (hTERT) 
catalytic subunit, an RNA component 
(hTR or hTERC): Human Telomerase 
RNA and Telomerase associated pro-
tein (TP1/TLP1)23,24. Telomerase activ-
ity has been detected in about 85% of 
human cancer samples and is associ-
ated with cell immortalization and the 
acquisition of malignancy, whereas the 
majority of normal tissues have low or 
no Telomerase activity25,26. Human Te-
lomerase reverse transcriptase (hTERT) 
catalytic subunit proved essential for 
cellular immortality and oncogenesis; 
hence, its detection provides a potential 
new cancer diagnostic possibility. In the 
present study, we sought to investigate 
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the potential of clinical usage of hTERT 
mRNA in urine sediments as a diagnos-
tic marker for bladder cancer.
SUBJECTS AND METHODS                             
This prospective study was conducted 
on (50-100ml) morning voided urine 
samples obtained from 39 patients with 
bladder cancer (31 were newly diag-
nosed cases of bladder cancer and 8 were 
follow-up patients). Fourteen patients 
with urological disorders not related to 
bladder cancer of matched age and sex 
(as control cases). All were collected 
from the Urology Department, Faculty 
of Medicine, Alexandria University; in 
the period between January 2007 and 
March 2008. The control group also in-
cluded 8 apparently healthy volunteers 
of matched age and sex. The study was 
approved by the University of Alexan-
dria, Faculty of Medicine Ethics Re-
view Board and informed consent was 
obtained from all patients who agreed 
to participate.
Cystoscopic biopsy was used as the ref-
erence standard for the identifi cation of 
bladder cancer. All urologic samples 
were coded and the results of the RT-
PCR assay were interpreted blind of 
the cytologic, or histologic diagnosis. 
Histopathological classifi cation of the 
urothelial tumours was done according 
to the WHO/ISUP consensus classifi ca-
tion 2004.27,28
Urine Cytology:
An aliquot of the sedimented urinary 
cell pellet was utilized for cytological 
examination which was performed us-
ing Papanicolaou and Hematoxylin and 
Eosin stained cytospin preparations.
RNA Extraction:
Another aliquot was utilized for fresh 
RNA extraction and RT-PCR based 
technology. Total RNA was prepared 
using the RNeasy minikit for animal 
cell RNA extraction (Qiagen, GmbH 
Germany) according to manufacturer’s 
recommendations. All RNA exractions 
were performed in a designated sterile 
laminar-fl ow hood with RNase-free 
labware. The integrity of the extracted 
RNA was confi rmed by running on 1% 
agarose gel and detection of the 18S and 
28S ribosomal subunits as bright, dis-
crete bands29. Samples with poor RNA 
quality were excluded from the study.
Multiplex hTERT/GAPDH RT-PCR:
A two-step RT PCR assay was per-
formed using Ready-To-Go RT-PCR 
Beads (Amersham Biosciences-UK 
Ltd.), which entailed fi rst strand com-
plementary DNA synthesis (cDNA) by 
addition of random hexamer primers, 
and template RNA (according to kit in-
structions); followed by specifi c primer 
amplifi cation in a multiplex reaction. 
Specifi c primers were added in a con-
centration of 25 picomoles for hTERT 
primers (5’-CGGAAGAGTGTCTG-
GAGCAA-3’, 5’-GGATGAAGCG-
GAGTCTGGA-3’) (9) and 2.5 pico-
moles for GAPDH primers (5’-TGG-
GATGGACTGTGGTCATGAG-3’, 
5’-ACTGGCGTCTTCACCACCAT-
GG-3’) (VBC-GENOMICS Bioscience 
Research Gmbh) in a 50 μl reaction. 
Each PCR batch included a sample 
without RNA as a negative control. 
Reactions were subjected to 35 PCR 
cycles of 94ºC for 60 seconds, 58ºC 
for 60 seconds and 72ºC for 60 seconds 
followed by 7 minutes extension step 
at 72ºC (Thermal Cycler, Biocycler 
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TC-S, V. GmbH, Austria. HVD-Life 
Sciences). The PCR products were ana-
lyzed by electrophoresis on an ethidium 
bromide stained 2.5% agarose gel in 
TBE buffer (Figure. 1). A sample was 
considered positive for the presence of 
hTERT mRNA based on the detection 
of a specifi c 145-bp amplicon. A sample 
was considered negative based on the 
absence of a 145-bp amplicon and the 
presence of a GAPDH-specifi c 250-bp 
amplicon.
Semiquantitative analysis of RT-PCR 
results:
Semiquantitative analysis using “Gel-
Pro Analyzer” version 4 (Media Cy-
bernetics, USA) was performed. This 
method employs using the house-
keeping gene ‘GAPDH’ as an inter-
nal positive control in each sample30,31 
to normalize hTERT expression for 
sample-to-sample differences in RNA 
input, RNA quality and RT-PCR assay 
effi ciency. The expression of hTERT 
mRNA relative to GAPDH mRNA 
was determined as a calculated ratio 
between the amounts of hTERT rela-
tive to that of GAPDH within the same 
lane.
Statistical Analysis:
The sensitivity of the RT-PCR assay 
and cytology in urologic specimens 
was defi ned as: The frequency of sam-
ples correctly identifi ed as malignant 
by the assay among the total number 
of patients with histologic confi rmation 
of bladder cancer. The specifi city was 
calculated as: The frequency of samples 
correctly identifi ed as non-malignant 
by the assay among the total number 
of participants without histologically 
proven bladder cancer. Mc Nemar’s 
chi-square test was used to determine 
the signifi cance of differences in the 
sensitivity of hTERT/GAPDH RT-PCR 
and urine cytology. Reciever Operating 
Curve (ROC) analysis using semiquan-
titative data was done to set a cut-off 
point to discriminate malignant from 
non-malignant cases. 
RESULTS                                                   
Clinicopathologic characteristics of 
the bladder cancer patients:
In the malignant study group, mean age 
of the patients was 61.7±10.3 years, with 
a peak age incidence during the seventh 
decade. Thirty-four cases were males 
and fi ve were females. The study includ-
ed 36 cases of urothelial cell carcinoma 
(92.3%) and 3 cases with squamous 
cell carcinoma (7.7%). The urothelial 
tumours were classifi ed according to 
WHO/ISUP consensus classifi cation27: 
one case (3%) was a papillary urothelial 
neoplasm of low malignant potential 
(PUNLMP), 10 cases (27%) were low 
grade papillary urothelial carcinoma, 
11 cases (30%) were high grade papil-
lary urothelial carcinoma and 12 cases 
(32%) were high grade invasive (non 
papillary) urothelial carcinoma. Cases 
were subsequently staged according to 
TNM system28; 43% were non-muscle 
invasive tumours and 57% were muscle 
invasive tumours.
Overall Sensitivity, Specifi city, Posi-
tive Predictive Value and Negative 
Predictive Value of hTERT/GAPDH 
RT-PCR:
The multiplex RT-PCR assay for hTERT 
expression in voided urine specimens 
showed an overall sensitivity of 83.8% 
and a specifi city of 72.7% (Table 1).
The hTERT mRNA expression was de-
tected in urologic specimens from 26 of 
31 (83.8%) patients with histopatholog-
ic confi rmation of bladder cancer and 
7 of 8 (87.5%) of follow-up patients, 
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with clinically diagnosed non-muscle 
invasive bladder cancer. False negative 
results were scored in 5 patients with 
histologically confi rmed bladder can-
cer. All of those cases showed evidence 
of intense infl ammatory infi ltrate in the 
tumour histologically, as well as by 
urine cytology.
Positive hTERT mRNA expression 
was detected in urine samples from 2 
patients with previous history of blad-
der cancer who were cancer-free by 
cystoscopy and upper tract imaging 
at the time of urine sample collection 
(Figure. 2). The urine analysis and cul-
tures indicated that the patients did not 
have urinary tract infections. Clinical 
follow-up of the patients confi rmed 
that the patients developed recurrence 
5 and 4 months, respectively, follow-
ing the hTERT/GAPDH RT-PCR assay 
positivity.
Based on Mc Nemar’s chi-square paired 
comparison of the 37 bladder cancer 
cases with pathologic confi rmation, the 
hTERT/GAPDH RT-PCR test demon-
strated signifi cantly higher sensitivity 
than the conventional urine cytology 
(83.8 % vs. 75.7%, p<0.0089).
The positive predictive value of the 
test defi ned as the probability that a 
positive hTERT/GAPDH RT-PCR as-
say is true-positive compared with the 
fi nal pathologic diagnosis was 83.8% 
in this study.
The negative predictive value, calcu-
lated as the probability that a negative 
hTERT/GAPDH RT-PCR assay is true-
negative compared with the fi nal patho-
logic diagnosis, was 72.7 %.
Semiquantitative Analysis of hTERT 
mRNA in urine samples:
Semiquantitative analysis of hTERT 
expression relative to GAPDH house 
keeping gene using “Gel-Pro Ana-
lyzer” version 4 (Media Cybernetics, 
USA) was performed. The mean ra-
tion of hTERT/GAPDH was observed 
to be higher in the malignant group 
relative to the benign cases. The differ-
ence between the mean ratio for benign 
cases (0.30 ± 0.35) and malignant cases 
(0.66 ± 0.46) was statistically sig-
nifi cant using the Mann Whitney test, 
p< 0.0001 (Table 2).
ROC curves were used to to assess 
the accuracy of hTERT/GAPDH ra-
tio in diagnosing malignant cases. The 
area under the curve (AUC) can range 
from 0-1. Diagnostic tests with AUC 
that approach 1 indicate a perfect dis-
criminator. In this study the positivity 
lies within the presence of malignancy 
and the negativity being its absence. 
The results showed an AUC of 0.84 ± 
0.06, which was signifi cantly better 
than indifference p<0.0001 (Figure. 3). 
Using the ROC curve a cut-off point of 
0.07 AU was proposed, with a sensi-
tivity of 97.3%. By elimination of the 
confounding factor of infl ammation the 
sensitivity of the test using the 0.07AU 
cut-off point increased from 97.3% to 
100% and the specifi city from 66% to 
68%. 
Comparison between the perfor-
mance of RT-PCR assay and Conven-
tional Cytopathology:
The sensitivity of the multiplex RT-PCR 
assay (83.8%) was signifi cantly higher 
than that for conventional cytology 
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(75.7%) (p=0.0089) (Table 3). Howev-
er, the specifi city of the assay was lower 
72.7% as opposed to 100%. 
When combining RT-PCR and urine cy-
tology, the sensitivity highly increased 
to reach 95%. However the specifi city 
remained constant at 72.7%. The posi-
tive predictive value rose to 86%, as 
well as the negative predictive value 
89%.







 for  malignancy♠
Positive 31 6 37
Negative 6 16 22
Total 37 22 59
Chi square 18.84
P value <0.0001*
Sensitivity 31 / 37= 83.8
Specifi city 16 / 22= 72.7
PPV 31 / 37= 83.8
NPV 16 / 22= 72.7
*: Statistically signifi cant at P≤0.05.
♠: Cases with benign urological disorders and healthy volunteers did not have cystoscopic biopsy, but 
were included in ‘negative for malignancy’ Group. 
Abb.: PPV: Positive predictive value, NPV: Negative predictive value.
Table 1: Relation between hTERT and histopathology (the gold standard).
Effi ciency of hTERT expression and 
Conventional Cytology:
The effi ciency of RT-PCR assay in low 
grade UCC (81.8%) was not much low-
er than that in high grade UCC (91.3%) 
possibly indicating that increased Te-
lomerase expression occurs early in 
bladder cancer tumourigenesis. In con-
trast, urine cytology revealed a poorer 
sensitivity in comparison to hTERT/










Range 0 -1 0.05- 2.60
Mean ± SD 0.30 ± 0.35 0.66 ± 0.46
Z of Man Whitney test 4.50P<0.0001*
Table 3: Comparison between the performance of the non invasive diagnostic modalities 
(hTERT RT PCR assay and cytopathology) of bladder cancer in voided urine specimens.
Parameters Sensitivity Specifi city PPV1 NPV2*
Telomerase RT-PCR 83.8* 72.7 79.5 83.8
Cytology 75.7* 100 100 72.7
Cytology + RT PCR in urine (either) 94.9 72.7 86 89
Chi square test comparing between sensitivity of cytology and RT-PCR for hTERT was 6.85 with a p 
value* 0.0089. Abbreviation:1:PPV: Positive predictive value, 2:NPV: Negative predictive value
Fig. 1: Multiplex PCR product. Lane M shows the standard 100bp molecular marker. Samples coded 
BLa – BLh show 2 amplicons, one at 145bp representing hTERT gene the other at 250bp representing 
the GAPDH gene. Sample BLi did not show GAPDH gene and hence was excluded from the study. A 





200bp     →
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Fig. 2: Flow chart of detection of hTERT mRNA in urinary samples of patients with a history of 
resected bladder cancer during follow up cystoscopy revealed cancer-free status. All tissue samples 
indicated by * had histopathologic assessment. Cytology was negative at the time of detection of the 
Telomerase marker. Samples codes are BR5 and BR7. Abbreviations: M, male; UCC, urothelial cell 
carcinoma, pTa: Superfi cial non invasive urothelial carcinoma, 
pT1: urothelial carcinoma infi ltrating the lamina propria, pT2: Urothelial carcinoma infi ltrating the 
muscularis propria of the bladder wall.
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Fig. 3: ROC curve analysis hTERT/GAPDH semiquantitative assay.
Fig. 4: Comparison between sensitivities of Telomerase and cytology in different tumour grades.
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DISCUSSION                                                  
There is a pressing need for a non inva-
sive method to diagnose carcinoma of 
the urinary bladder. To date, however 
cystoscopy remains the gold standard 
not only for primary diagnosis of tu-
mours, but is repeated at approximately 
3-6 months interval for follow-up of re-
currence.
At present, cytology is accepted as the 
gold standard non-invasive method for 
screening of bladder carcinoma in both 
symptomatic patients and the general 
population, as it is non invasive, safe, 
and inexpensive.10,32
Urine cytologic examination is “mor-
phology-based” and therefore inevi-
tably demonstrates a low sensitivity 
in low-grade tumours since the cy-
tologic abnormality is slight. It pos-
sesses a good overall median specifi c-
ity of 99% (83–100%) and an accept-
able overall median sensitivity of 34% 
(20%–53%)33. In the present study the 
specifi city of urine cytology was 100% 
and the overall sensitivity was higher 
than that reported in the literature be-
ing 75.7%. This may be attributed to the 
larger percentage of high grade tumours 
in our cohort.
Earlier studies reported strong correla-
tion between hTERT expression and 
detectable Telomerase enzyme34-36. Su-
zuki et al. demonstrated hTERT mRNA 
expression in 100% of bladder can-
cer tumour tissue37. Ito et al. observed 
that only the expression of hTERT is 
specifi cally associated with more than 
90% of urothelial cancers6. Limitations 
of the Telomeric Repeat Amplifi cation 
Protocol (TRAP) assay used to measure 
Telomerase enzyme activity including; 
rapid degradation of the protein enzyme 
in the hostile urinary environment and 
the need for large numbers of cells in 
urine are largely overcome by the use 
of RT-PCR-based detection of hTERT 
mRNA. Scientists have claimed that an 
RT-PCR assay may detect a single posi-
tive cell amidst hundred negative cells38. 
In the same context, the work of Muller 
et al. on bladder carcinoma concluded 
that RT-PCR detection of hTERT ap-
pears to be several orders of magnitude 
more sensitive than TRAP assay.39
The multiplex hTERT/GAPDH RT-PCR 
applied in this study, correctly predicted 
bladder cancer in 31 of 37 patients (sen-
sitivity of 83.8%), with a 72.7% speci-
fi city and a positive predictive value 
of 83.8% irrespective of grade or stage 
of the tumour.
The specifi city of the present study 
(72.7%) was found to be lower than 
that reported in some earlier studies 
where the specifi city ranged from 90% 
to 100%5-7,19,39-41. However, other stud-
ies such as Neves et al.40 and Morsi et 
al.41 reported a lower specifi city of 69% 
and 66%, respectively. The specifi city 
data does not support the use of hTERT 
mRNA in place of cytology, however 
the improved sensitivity of the assay 
suggests its potential utility as an ad-
junct to cytology.
In two of the follow-up patients (BR5 
and BR7, Figure. 2) which have been 
initially diagnosed as low grade papil-
lary UCC, pT1 lesion and carcinoma 
in-situ, respectively, (both known to 
present a high risk for recurrence) the 
results of the hTERT/GAPDH RT-PCR 
were positive in the follow-up urine 
samples. Meanwhile, their cystoscopic 
and cytologic examinations were nega-
tive for malignancy. Both patients de-
veloped recurrence within 5 months and 
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4 months, respectively, of disease-free 
interval. This fi nding suggests a role for 
Telomerase expression in the early de-
tection of recurrence. Hence, molecular 
changes contributing to cancer recur-
rence could be highlighted by hTERT/
GAPDH RT-PCR assay, prior to any 
morphologic changes. A similar fi nding 
was reported in 3/3 follow-up patients 
in a study by Bialkowska-Hobrzanska 
et al.5 Regarding its potential capability 
in the prediction of tumour recurrence, 
RT-PCR assay may be useful prior to the 
cystoscopy procedure, as it may alter 
the management strategy of the operat-
ing surgeon, especially when no tumour 
lesion can be identifi ed grossly. Follow-
ing discussions with urology surgeons 
through personal contact, the surgeons 
suggested that extra caution should be 
taken in the follow-up of these cases 
and surgeons may accordingly opt to:
A. Take multiple random cold-cup bi-
opsies from the bladder wall,
B. Obtain a barbotage cytology sam-
ple,
C. Assess the upper urinary tract to ex-
clude other tumours,
D. Reduce the interval before the fol-
lowing cystoscopic procedure.
In this study we observed a higher di-
agnostic sensitivity of the hTERT RT-
PCR assay (31/37, 83.8%) as compared 
to the conventional cytology (28/37, 
75.7%). We found some cases of discor-
dance, in which cytology was negative 
but Telomerase expression was positive 
5 out of 7 cases (71.4%). These samples 
contained very few cancer cells, which 
could have been insuffi cient for cyto-
logical evaluation but detectable by RT-
PCR. Follow-up of the cases revealed 
histological evidence of low grade tu-
mours. Nevertheless, some discordanc-
es were observed where cytology was 
positive but Telomerase was negative 
(4 out of 6 cases). This type of discor-
dance was prevalent among high-grade 
cancers. A possible explanation for 
this discrepancy is simply the degrada-
tion of Telomerase in urinary sediment 
samples in aggressive necrotic tumours. 
Taken together, these fi ndings suggest 
that the combination of cytological ex-
amination with urinary Telomerase may 
improve the sensitivity and specifi city 
of non-invasive screening for bladder 
cancer. In fact, on calculating the com-
bined sensitivity of urinary hTERT 
mRNA detection and conventional cy-
topathology, the sensitivity improved 
to 94.6%.
The specifi city of the telomerase expres-
sion by RT-PCR is illustrated in patients 
of the benign group and healthy volun-
teers. In our results there was a high 
positive prevalence in those patients, 
which greatly compromised the speci-
fi city to 72.7%. Patients who showed 
a false-positive Telomerase result, all 
showed evidence of chronic or severe 
infl ammation as evidenced by cytology 
and urine analysis.
Using the calculated hTERT/GAPDH 
ratios for the study groups, a ROC curve 
was plotted. Using the previously pub-
lished cut-off value 0.2 AU proposed by 
Bialowska-Hobrzanska et al.5 the curve 
displayed a sensitivity of 86.5% and a 
specifi city of 66.7%. On the other hand, 
the present study deduced an optimum 
experimental cut-off value of 0.07AU 
which displayed a better sensitivity of 
97.3% and a specifi city of 66.7%. The 
low specifi city of hTERT mRNA is 
mainly attributed to the high false-posi-
tive rate in patients of the benign group, 
which is most probably due to the pres-
ence of Telomerase positive infl amma-
tory cells in urine. In the absence of in-
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fl ammation, whilst using a cut-of value 
of 0.07, the sensitivity of RT-PCR assay 
rose up to 100%.
In conclusion, as patient compliance is 
greater with procedures that are non-
invasive, the combination of hTERT/
GAPDH assay with cytology could al-
low the early diagnosis of bladder car-
cinoma, particularly so, for the early 
detection of bladder carcinoma recur-
rence following treatment. It could also 
be of value in evaluating patients at 
high risk for developing bladder can-
cer, including those exposed to occupa-
tional carcinogens, Future prospective 
multi-centre studies conducted with 
standardized specimen collection and 
storage procedures are strongly recom-
mended to further validate the clinical 
usefulness of implementing hTERT RT-
PCR assay as a diagnostic and screen-
ing method for bladder cancer in voided 
urine specimens.
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